This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

ISIS-2 trial

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

17187 patients entering 417 hospitals a median of 5 hours after the onset of the symptoms of acute myocardial infarction were randomised with placebo control to:

  • a 1 hr i.v. infusion of 1.5 MU of streptokinase
  • one month of 160 mg/day enteric-coated aspirin
  • both of the above
  • none of the above

Both streptokinase and aspirin reduce mortality when compared to placebo:

  • streptokinase alone: 9.2% vs. 12.0% (2p < 0.00001)
  • aspirin alone: 9.4% vs. 11.8% (2p < 0.00001)

The use of both agents together gave a synergistic reduction in mortality:

  • aspirin + streptokinase: mortality = 8.0%
  • placebo: mortality = 13.2%
  • this represents an odds reduction for death of 42%

There was no significant increase in serious side-effects such as intracranial haemorrhage or bleeds requiring transfusion.

Reference:

  • Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected acute myocardial infarction: ISIS-2. (1988). Lancet, 2, 349-60.

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.